Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 3rd day
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by Chritterson May 25, 2021 9:02am
174 Views
Post# 33258880

RE:RE:RE:RE:3rd day

RE:RE:RE:RE:3rd dayJust for everyone getting fed wrong information, If the RS gets voted in it doesnt mean the Reverse Split happens that day, It could take weeks or even months to go thru. If you are serious and want your questions answered dont go to the Pumper groups like Facebook or The Claritas Investors group and have to sign up, CEO.CA is the best place to come. Here as you can see all the fake pumpers attack everyone if you talk Ill of the company.


AngelaL wrote: Based on the large current short position (which is published), this will be a short squeeze of epic proportion. Why? Because there are not enough days left before the RS takes place for the shorts to physically cover their positions without a truly massive increase in share price. The quality of the company and its technology are too good for the strategy of the shorts to work. It will be a bloodbath. 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities